( or therapeutic intervention of Alzheime...)Modified Drug Therapy for Alzheimers Disease,Health

or therapeutic intervention of Alzheimer's disease. His most recent work was published in the May 17 issue of the Journal of Medicinal Chemistry.

Ghosh also helped direct CoMentis in the generation of beta-secretase inhibitor drugs. The treatment molecule, beta-secretase inhibitor CTS-21166, is the culmination of this work.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Ghosh said. "It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential."

The trial, comprised of 48 healthy volunteers, will measure safety, tolerability and pharmacokinetics of CTS-21166 at various doses. The company expects to begin generating human clinical data by the end of 2007 and to begin phase II studies in Alzheimer's patients in 2008. The drug could be administered at any stage of the disease, Ghosh said.

These clinical trial phases are the first steps in a lengthy process necessary before the Food and Drug Administration approves a drug to be available on the market.




'"/>




Page: 1 2
Related medicine news :

1. Modified antibiotic may support fight cancer
2. Malaria To Be Tackled By Genetically Modified Mosquitoes
3. Stroke Rehabilitation Through Modified Video Games
4. Genetically Modified Cells Attack Tumors
5. TB can Be Eradicated in the U.S With Modified Guidelines: Study
6. Modified Ligament Surgery Improves Outcomes Players, Athletes
7. Cancer Doctors Okays Controversial Prostate Therapy
8. Consensus on "Combination Therapy" for Breast Cancer
9. Gene Therapy shows promise in treating Hemophilia
10. "Make AIDS Therapy affordable" - Physicians demand
11. Hormone replacement Therapy a headache